New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 23, 2013
07:14 EDTTSROTESARO achieves primary endpoint in two Phase 3 trials
TESARO announced top-line results for two Phase 3 trials of rolapitant, an investigational neurokinin-1 receptor antagonist in development for the prevention of chemotherapy-induced nausea and vomiting. The primary endpoint was successfully achieved in each trial and preparations are ongoing in support of a New Drug Application submission for oral rolapitant to the U.S. FDA. The company said, "Despite the availability of preventative therapies and established treatment guidelines for CINV, a significant number of cancer patients still suffer from the debilitating side effects of delayed nausea and vomiting. We are enthusiastic about the potential for this product candidate, with a profile that may include an extended half life, convenient, single-dose oral and intravenous formulations and a lack of CYP3A4-mediated drug interactions." TESARO continues to enroll patients receiving HEC in a third and final Phase 3 trial of rolapitant, and preparations in support of a mid-2014 NDA submission for oral rolapitant are ongoing. Full analyses of data from all three rolapitant pivotal Phase 3 trials will be submitted for presentation at a future medical meeting.
News For TSRO From The Last 14 Days
Check below for free stories on TSRO the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 7, 2014
07:27 EDTTSROAmerican Association of Cancer Research to hold annual meeting
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use